Prognostic factors of lethality in patients with cardiorenal syndrome

被引:0
|
作者
Mirabal, Ismary Ferrer [1 ,2 ]
Hernandez, Dianeli L. Reyes [1 ]
机构
[1] Hosp Univ Clin Quirurg Arnaldo Milian Castro Villa, Serv Med Interna, Santa Clara, Villa Clara, Cuba
[2] Hosp Arnaldo Milian Castro, Serv Med Interna, Ave Hosp Nuevo,e-Doble Via Circunvalac, Santa Clara 50200, Villa Clara, Cuba
来源
CORSALUD | 2024年 / 15卷 / 01期
关键词
Cardiorenal syndrome; Prognosis; Lethality; DECOMPENSATED HEART-FAILURE; WORSENING RENAL-FUNCTION; CLASSIFICATION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: It is evident that cardiorenal syndrome constitutes an important medical-health problem in contemporary medicine. Objective: To determine the clinical and epidemiological aspects and the values o f complementary tests that have discriminatory power to predict death in patients with cardiorenal syndrome. Method: An analytical observational case -control study was conducted on 161 patients with cardiorenal syndrome at the Hospital Arnaldo Mili & aacute;n Castro (Villa Clara, Cuba), from 2015 to 2018. The case group included the deceased patients (67) and the control group, those discharged alive (94). Results: The male sex slightly predominated in both groups (50.7% and 51.1%); mean age close to 71 years; white skin and cardiorenal syndrome type 3, with a personal pathological history of chronic kidney disease (145; 90.1%); chronic ischemic heart disease (119; 73.9%); high blood pressure (108; 67.1%), anemia (107; 66.5%) and chronic heart failure (109; 67.7%), with significant differences in complementary tests and vital signs. Conclusions: The clinical and epidemiological aspects and values of complementary tests that have discriminatory power to prognosticate lethality in patients with cardiorenal syndrome are anemia and diabetes mellitus, linked or not to high blood pressure and the manifestation of chronic ischemic heart disease and chronic kidney disease; the combination of these last three entities; creatinine above 198.5 ,umol/L, uric acid above 527 ,umol/L, urea greater than 6.4 ,umol/L, potassium above 3.9 mEq/L and respiratory frequency greater than 18 breaths per minute.
引用
收藏
页码:22 / 34
页数:13
相关论文
共 50 条
  • [21] Acute cardiorenal syndrome in patients with IE
    Kotova, E. O.
    Getiya, T. S.
    Lazarev, P. V.
    Filatov, V. L.
    Kobalava, Z. H. D.
    Moiseev, V. S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 476 - 476
  • [22] CYSTATIN C IS DIAGNOSTIC AND PROGNOSTIC FACTOR OF THE DEVELOPMENT OF CARDIORENAL SYNDROME IN COMORBID PATIENTS WITH ARTERIAL HYPERTENSION
    Dunaieva, Inna
    Bilovol, Olexandr
    JOURNAL OF HYPERTENSION, 2024, 42
  • [23] Prognosis of cardiorenal syndrome in patients with acute coronary syndrome
    Luis Cabrerizo-Garcia, Jose
    Zalba-Etayo, Begona
    Perez-Calvo, Juan Ignacio
    MEDICINA CLINICA, 2012, 139 (10): : 437 - 440
  • [24] Prognostic factors about morbidity and lethality in head injury
    Melo, JRT
    Oliveira, J
    da Silva, RA
    Moreira, ED
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2005, 63 (04) : 1054 - 1057
  • [25] RISK FACTORS FOR PROGRESSIVE CARDIORENAL SYNDROME IN PATIENTS WITH CHRONIC KIDNEY DISEASE: THE CRIC STUDY
    Chen, Jing
    He, Jiang
    ATHEROSCLEROSIS, 2024, 395
  • [26] Risk factors for progressive cardiorenal syndrome in patients with chronic kidney disease: the CRIC study
    Chen, Jing
    He, Jiang
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I2327 - I2327
  • [27] Risk factors for progressive cardiorenal syndrome in patients with chronic kidney disease: the CRIC study
    Chen, Jing
    He, Jiang
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [28] Importance of the Cardiorenal Unit for the Management and Monitoring of Highly Complex Patients with Cardiorenal Syndrome
    Leon-Roman, Juan Carlos
    Azancot, Maria
    Patricio-Liebana, Marc
    Zamora Carrillo, Jorge Ivan
    Soler, Maria Jose
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [29] Experience with the use of semaglutide in cardiorenal syndrome patients followed in a cardiorenal unit (CRU)
    Marques Vidas, Maria De San Miguel
    Crespo, Silvia
    Cobo, Marta
    Montero, Esther
    Lopez-Azor, Juan Carlos
    Gonzalez, Julia
    Maria Portoles, Jose
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1063 - I1063
  • [30] Experience with the use of semaglutide in cardiorenal syndrome patients followed in a cardiorenal unit (CRU)
    Vidas, Maria De San Miguel Marques
    Crespo, Silvia
    Cobo, Marta
    Montero, Esther
    Lopez-Azor, Juan Carlos
    Gonzalez, Julia
    Portoles, Jose Maria
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39